- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00124189
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
December 22, 2015 updated by: Geron Corporation
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Imetelstat Sodium (GRN163L) is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems.
Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells.
Inhibition of telomerase may result in antineoplastic effects.
High telomerase levels and short telomere lengths correlate with other markers of poor prognosis in patients with chronic lymphoproliferative disease.
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Center
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Medical Center
-
New York, New York, United States, 10021
- Weill Medical College of Cornell University
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University James Cancer Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age or older
- Male or female
- Chronic lymphoproliferative disease with related biology or similar clinical pattern to B-Cell Leukemia (CLL)including: small lymphocytic lymphoma (SLL), T cell prolymophocytic leukemia (T-PLL), B cell prolymphocytic leukemia (B-PLL), mantle cell lymphoma or other non-Hodgkins lymphoma in leukemic phase (peripheral blood circulating malignant cells present), Waldenstrom's macroglobulinemia
- Must have relapsed from or be refractory to prior therapeutic regimens
- Patients with CLL or SLL must have received at least one prior purine analogue-based chemotherapy regimen (eg, fludarabine, pentostatin or cladribine)
- If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction > 50%
- ECOG performance status 0-2
- Life expectancy 3 months or greater
Exclusion Criteria:
- Pregnant or lactating women
- Active 2nd malignancy or history of another malignancy within 2 years, except:treated, non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a or b prostate cancer
- Chemotherapeutic agents within 4 weeks prior to study
- High dose CTX with stem cell support within 6 months prior to study
- Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study
- Immunotherapy or biological response modifiers within 4 weeks prior to study
- Systemic hormonal therapy within 4 weeks prior to study
- Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
- Radiotherapy within 4 weeks prior to study
- Active autoimmune disorder
- Central nervous system or leptomeningeal involvement
- Clinically significant cardiovascular disease
- Known HIV infection
- Serious/active infection
- Surgical procedure within 2 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: open label
Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
|
Weekly intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or recommended phase II dose of GRN163L in patients with relapsed or refractory chronic lymphoproliferative disease
Time Frame: First 3 weeks
|
First 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PK and PD
Time Frame: Measured in the first 6 weeks
|
Measured in the first 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
July 25, 2005
First Submitted That Met QC Criteria
July 25, 2005
First Posted (Estimate)
July 27, 2005
Study Record Updates
Last Update Posted (Estimate)
December 24, 2015
Last Update Submitted That Met QC Criteria
December 22, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRN163L CP04-151
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphoproliferative Diseases
-
Becton, Dickinson and CompanyCompletedChronic Lymphoproliferative Diseases (CLPD)United States, Switzerland, Spain, United Kingdom, Portugal
-
Becton, Dickinson and CompanyRecruitingChronic Lymphoproliferative Diseases (CLPD)Switzerland, United States, Portugal, Spain
-
Gruppo Italiano Studio LinfomiCompletedBendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative DisordersRelapsed or Refractory Chronic Lymphoproliferative DisordersItaly
-
Hoffmann-La RocheCompletedLymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, CancerSerbia
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicKorea, Republic of, Japan
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicJapan
-
GlaxoSmithKlineGenmabCompletedLeukaemia, Lymphocytic, ChronicSweden
-
Gruppo Italiano Studio LinfomiCompletedChronic Lymphocytic LeukaemiaItaly
-
Royal Marsden NHS Foundation TrustCompleted
Clinical Trials on GRN163L
-
Geron CorporationCompleted
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedGlioblastoma | Gliosarcoma | Ependymoma | Anaplastic Astrocytoma | Oligodendroglioma | Anaplastic Ependymoma | Giant Cell Glioblastoma | Astrocytoma, Grade II | Brainstem TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnRhabdomyosarcoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Hepatoblastoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Recurrent Childhood Liver Cancer
-
Geron CorporationCompletedPrimary Myelofibrosis | Secondary Myelofibrosis | Myeloid MalignanciesUnited States
-
Geron CorporationRecruiting
-
Geron CorporationActive, not recruitingMyelodysplastic SyndromesUnited States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaboratorsRecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromesAustralia, France, Germany
-
Geron CorporationCompletedMultiple MyelomaUnited States
-
Geron CorporationCompletedSolid Tumor MalignanciesUnited States
-
Geron CorporationCompleted